Evidence map›Paper›PMID 34604043›Full record

ReviewFrontiers in oncology2021

Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical Review.

Byeongsang Oh, Frances Boyle, Nick Pavlakis, Stephen Clarke, Alex Guminski, Thomas Eade, Gillian Lamoury, Susan Carroll, Marita Morgia, Andrew Kneebone and 8 more

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07607548 (A 8-week, Randomized, Double-blind, and Placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on Proinflammatory Mechanisms Induced by Systemic Treatment in Women With Breast Cancer), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07607548 nacompletednot on this mapstarted 2022, after this paper: background citation

A 8-week, Randomized, Double-blind, and Placebo-controlled Study Evaluating the Effect of Probiotic Supplementation on Proinflammatory Mechanisms Induced by Systemic Treatment in Women With Breast Cancer

TypeinterventionalSponsorPoznan University of Medical SciencesRan2022 to 2024Enrolled60ConditionsBreast Cancer, Probiotic TherapyArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Immunomodulatory effects ofFrontiers in immunology · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Byeongsang OhNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Frances BoyleCancer Care Service, Mater Hospital, North Sydney, NSW, Australia.
Nick PavlakisNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Stephen ClarkeNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Alex GuminskiNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Thomas EadeNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Gillian LamouryNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Susan CarrollNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Marita MorgiaNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Andrew KneeboneNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
George HrubyNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Mark StevensNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Wen LiuUniversity of Kansas Medical Center, Kansas City, KS, United States.
Brian CorlessNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Mark MolloyBowel Cancer and Biomarker Laboratory, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Towia LibermannBeth Israel Deaconess Medical Center (BIDMC) Genomics, Proteomics, Bioinformatics and Systems Biology Center, Beth Israel Deaconess Medical Center, Boston, MA, United States.
David RosenthalHarvard Medical School, Boston, MA, United States.
Michael BackNorthern Sydney Cancer Centre, Royal North Shore Hospital, St Leonards, NSW, Australia.
Mater Health Services · AURoyal North Shore Hospital · AUUniversity of Sydney · AUUniversity of Kansas Medical Center · USBeth Israel Deaconess Medical Center · USHarvard University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidence suggests that the gut microbiome is associated with both cancer chemotherapy (CTX) outcomes and adverse events (AEs). This review examines the relationship between the gut microbiome and CTX as well as the impact of CTX on the gut microbiome. A literature search was conducted in electronic databases Medline, PubMed and ScienceDirect, with searches for "cancer" and "chemotherapy" and "microbiome/microbiota". The relevant literature was selected for use in this article. Seventeen studies were selected on participants with colorectal cancer (CRC; n=5), Acute Myeloid Leukemia (AML; n=3), Non-Hodgkin's lymphoma (n=2), breast cancer (BCa; n=1), lung cancer (n=1), ovarian cancer (n=1), liver cancer (n=1), and various other types of cancers (n=3). Seven studies assessed the relationship between the gut microbiome and CTX with faecal samples collected prior to (n=3) and following CTX (n=4) showing that the gut microbiome is associated with both CTX efficacy and toxicity. Ten other prospective studies assessed the impact of CTX during treatment and found that CTX modulates the gut microbiome of people with cancer and that dysbiosis induced by the CTX is related to AEs. CTX adversely impacts the gut microbiome, inducing dysbiosis and is associated with CTX outcomes and AEs. Current evidence provides insights into the gut microbiome for clinicians, cancer survivors and the general public. More research is required to better understand and modify the impact of CTX on the gut microbiome.

Indexed as

adverse eventsbiomarkercancerchemotherapygut microbiome

Identifiers

PMID34604043
PMCPMC8481611
OpenAlexW3201516608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.